128 results
8-K
EX-99.1
AKBA
Akebia Therapeutics Inc.
9 May 24
Akebia Therapeutics Reports First Quarter 2024 Financial Results
7:03am
Expenses: Research and development expenses were $9.7 million for the first quarter of 2024 compared to $19.7 million for the first quarter of 2023 … sold
Operating expenses
Research and development
Selling, general and administrative
License expense
Restructuring
Total operating expenses
Loss from
8-K
EX-99.1
7lewiwsguzxk5dp
14 Mar 24
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
4:18pm
8-K
EX-99.1
h4nro ugko0r
8 Nov 23
Akebia Therapeutics Reports Third Quarter 2023 Financial Results
7:33am
8-K
EX-99.1
auice09m
25 Aug 23
Akebia Therapeutics Reports Second Quarter 2023 Financial Results
8:14am
S-8
EX-99.1
nz1n0o
6 Jun 23
Registration of securities for employees
4:18pm
8-K
EX-99.1
i65i ys88e6bkv
8 May 23
Akebia Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
7:41am
8-K
EX-99.1
7o0ss85xbtnj ofhi6c
3 Nov 22
Akebia Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
4:33pm